secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2022-10-14T23:59:59+00:00
Accession:  0001193125-22-262375
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara and Enliven hold investor call on definitive merger; Enliven to become wholly owned subsidiary
--------------------------------------------------------------------------------

- Merger agreement provides for Enliven to survive as wholly owned subsidiary of Imara via a reverse merger.
- Joint investor conference call held on October 13, 2022 to discuss the transaction and its rationale.
- No deal value, premium, or expected close date disclosed in this filing or the appended transcript excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522262375/0001193125-22-262375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522262375/d397742d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-262375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer